Literature DB >> 12716755

Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes.

Ayad A Jaffa1, Ramon Durazo-Arvizu, Deyi Zheng, Daniel T Lackland, Sujata Srikanth, W Timothy Garvey, Alvin H Schmaier.   

Abstract

The relevance and significance of the plasma kallikrein/kinin system as a risk factor for the development of vascular complications in diabetic patients was explored in a cross-sectional study. We measured the circulating levels of plasma prekallikrein (PK) activity, factor XII, and high-molecular weight kininogen in the plasma of 636 type 1 diabetic patients from the Diabetes Control and Complications Trial/Epidemiology and Diabetes Intervention and Complications Study cohort. The findings demonstrated that type 1 diabetic patients with blood pressure > or =140/90 mmHg have increased PK levels compared with type 1 diabetic patients with blood pressure <140/90 (1.53 +/- 0.07 vs. 1.27 +/- 0.02 units/ml; P < 0.0001). Regression analysis also determined that plasma PK levels positively and significantly correlated with diastolic (DBP) and systolic blood pressures (SBP) as continuous variables (r = 0.17 and 0.18, respectively; P < 0.0001). In multivariate regression analysis, the semipartial r(2) value for PK was 2.93% for SBP and 2.92% for DBP (P < 0.0001). A positive correlation between plasma PK levels and the urinary albumin excretion rate (AER) was also observed (r = 0.16, P < 0.0001). In categorical analysis, patients with macroalbuminuria had a significantly higher level of plasma PK than normoalbuminuric patients (1.45 +/- 0.08 vs. 1.27 +/- 0.02 units/ml; P < 0.01), whereas microalbuminuric patients had an intermediate PK value (1.38 +/- 0.05 units/ml; P = NS). Among patients in the microalbuminuric subgroup, we observed a positive and independent correlation between PK and AER in univariate and multivariate regression analysis (r = 0.27, P < 0.03; n = 63). We concluded that in type 1 diabetes, 1) PK levels are elevated in association with increased blood pressure; 2) PK levels are independently correlated with AER and are categorically elevated in patients with macroalbuminuria; and 3) although the positive correlation between PK and AER within the subgroups of patients with microalbuminuria suggest that PK could be a marker for progressive nephropathy, longitudinal studies will be necessary to address this issue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716755     DOI: 10.2337/diabetes.52.5.1215

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  26 in total

1.  Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.

Authors:  James A MacKenzie; Kristen A Roosa; Brooks B Gump; Amy K Dumas; Kestutis G Bendinskas
Journal:  Appl Physiol Nutr Metab       Date:  2010-08       Impact factor: 2.665

2.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

3.  Multivariate Generalized Linear Mixed Models With Random Intercepts To Analyze Cardiovascular Risk Markers in Type-1 Diabetic Patients.

Authors:  Miran A Jaffa; Mulugeta Gebregziabher; Deirdre K Luttrell; Louis M Luttrell; Ayad A Jaffa
Journal:  J Appl Stat       Date:  2015-11-26       Impact factor: 1.404

4.  Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator.

Authors:  J S Keum; M A Jaffa; L M Luttrell; A A Jaffa
Journal:  J Biol Regul Homeost Agents       Date:  2014 Oct-Dec       Impact factor: 1.711

5.  Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC.

Authors:  Miran A Jaffa; Ionut Bebu; Deirdre Luttrell; Barbara H Braffett; John M Lachin; Kelly Hunt; Maria Lopes-Virella; Louis Luttrell; Timothy J Lyons; Ayad A Jaffa
Journal:  Diabetes       Date:  2020-08-21       Impact factor: 9.461

6.  A Likelihood Based Approach for Joint Modeling of Longitudinal Trajectories and Informative Censoring Process.

Authors:  Miran A Jaffa; Ayad A Jaffa
Journal:  Commun Stat Theory Methods       Date:  2018-09-19       Impact factor: 0.893

Review 7.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 8.  Hypertension and the bradykinin system.

Authors:  Jagdish N Sharma
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 9.  Cardiovascular implications of proteinuria: an indicator of chronic kidney disease.

Authors:  Varun Agrawal; Victor Marinescu; Mohit Agarwal; Peter A McCullough
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

10.  Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes.

Authors:  Miran A Jaffa; Deirdre Luttrell; Alvin H Schmaier; Richard L Klein; Maria Lopes-Virella; Louis M Luttrell; Ayad A Jaffa
Journal:  Diabetes       Date:  2015-11-24       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.